17
2020-02
Suzhou Kintor Obtained Approval to Conduct Clinical Trials for SMO Antagonists in China
On February 17, 2020, National Medical Products Administration officially granted the clinical trials notification to Suzhou Kintor Pharmaceuticals, Inc.(hereinafter referred to as “Suzhou Kintor") and agreed to approve clinical trials to be conducted on the SMO antagonist, GT1708F.
13
2019-12
Ms. Lu Yan Serves as Kintor's Chief Financial Officer
[Suzhou, December 13, 2019] Kintor Pharmaceutical Limited and its subsidiaries (the "Group") officially announced the appointment of Ms. Lu Yan as Chief Financial Officer who would be responsible for our capital market strategy, financial planning, investor relations and internal controls
25
2019-10
[Suzhou, China, October 25, 2019] Kintor Pharmaceutical Limited (the parent company of Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor")) and its subsidiaries (the "Group")announced completion of a financing of USD45 million in September 2019, which was a new round of financing after Series C investment of RMB288 million in February 2018. This round of investment was led by the Shanghai Free Trade Zone Fund, followed by Huajin Capital, CCB Technological Innovation Fund, Yicheng Hongtai, Yirongchuang and Guangzhou Chengfa. The original investor, Highlight Medical, also participated in this round of investment.
20
2019-08
mTOR Inhibitor Developed by Suzhou Kintor Obtained Approval for Clinical Trials in China
[Suzhou, August 20, 2019] National Medical Products Administration officially granted a clinical trial approval to Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") on commencement of clinical trials of the drug (GT0486) as an mTOR inhibitor. The drug (GT0486) is a novel mTORC1 / mTORC2 inhibitor (the second generation of mTOR inhibitor) which is indicated for advanced solid tumors. Currently, there is no second generation of mTOR inhibitors on the market in China, and there are huge unmet clinical needs in the research area.
19
2019-08
[Suzhou, August 19, 2019]Suzhou Kintor Pharmaceuticals, Inc. (“Suzhou Kintor") and CMAB Biopharma (Suzhou) Inc. ("CMAB") announced together a comprehensive strategic cooperation agreement on the development and production of ALK-1 monoclonal antibody in Suzhou Biopharma Industrial Park (BioBAY).
21
2019-06
Suzhou Kintor Won "Extraordinary Biopharmaceutical Enterprise Award" of China Financing in 2019
[June 21, 2019, Hong Kong, China] The awarding ceremony of the "2019 China Financing Awards" sponsored by "China Financing", a high-end financial magazine on Hong Kong capital market, was successfully held in Hong Kong. Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor"), together with nine pharmaceutical enterprises such as WuXi Biologics, Henlius, CanSinoBio, Innovent Biologics and Hua Medicine, won "Extraordinary Biopharmaceutical Enterprise Award" of China Financing in 2019. Dr. Youzhi Tong, Chairman and Chief Executive Officer of Suzhou Kintor , was invited to attend the ceremony and accept the award on behalf of the company.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn